Lynkuet (Elinzanetant): The Newest Non-Hormonal Hot Flash Treatment

Lynkuet (generic name elinzanetant) is a non-hormonal oral medication that treats moderate-to-severe hot flashes and night sweats during menopause. It works by blocking two receptors in the brain — NK-1 and NK-3 — that together control the thermoregulatory misfire that causes vasomotor symptoms (VMS). During menopause, declining estrogen disinhibits a cluster of neurons in the hypothalamus called KNDy neurons. These neurons become hyperactive and send false 'too hot' signals to the body's temperature control center, triggering the cascade we recognize as a hot flash: skin flushing, sweating, and a sudden urge to fan yourself. Elinzanetant calms those neurons by blocking the neurokinin receptors they signal through. Bayer developed the drug, and the FDA approved it in late 2025 under the brand name Lynkuet, making it the second drug in the neurokinin-antagonist class — after fezolinetant (Veozah) — to reach market in the US.

Elinzanetant reduced the frequency of moderate-to-severe hot flashes by 62 to 66% at 12 weeks in the OASIS-1 and OASIS-2 pivotal trials. The drug significantly outperformed placebo, with reductions visible as early as week 1 and continued improvement through 26 weeks of follow-up. Compared to baseline, women taking elinzanetant 120mg daily went from a median of 10+ hot flashes per day to under 4. In OASIS-3, which extended the study to 52 weeks, the benefit was sustained without loss of efficacy. The drug also reduced the severity of remaining hot flashes — meaning the ones that broke through were milder and shorter — and it reduced night sweats with similar magnitude. For comparison, HRT typically reduces hot flashes by 75–85%, while supplements like black cohosh show 20–30% effects that are not consistently larger than placebo.

Lynkuet and Veozah work in the same neighborhood but block different receptor combinations, and that difference matters for symptom coverage. Veozah (fezolinetant) blocks only the NK-3 receptor. Lynkuet (elinzanetant) blocks both NK-1 and NK-3. The NK-1 receptor is heavily involved in sleep regulation, mood, and the stress response, which is why elinzanetant shows additional benefits beyond hot flashes — meaningful improvements in sleep quality, fatigue, and menopause-related mood symptoms in trial data. Veozah's benefits are more narrowly focused on the hot flashes themselves. The other practical difference: Veozah requires monthly liver enzyme testing for the first three months because of liver injury cases seen in trials. Lynkuet does not have the same liver-monitoring requirement after the initial three months. For a direct breakdown of fezolinetant, our [Veozah hot flash guide](/blog/veozah-fezolinetant-for-hot-flashes-2026-guide) is worth a read.

Lynkuet is best suited for women who have moderate-to-severe vasomotor symptoms and either cannot or choose not to take HRT. The clearest candidates are breast cancer survivors, women with a personal history of estrogen-sensitive cancers, women with strong family histories that make hormones a difficult conversation, and women with unprovoked blood clots in their past. The drug is also a strong option for women who have tried HRT and found the breast tenderness, breakthrough bleeding, or mood effects intolerable. Lynkuet is not a substitute for HRT for women who need bone, brain, or cardiovascular protection — those benefits come specifically from estrogen, and neurokinin antagonists do not replicate them. If you are weighing the broader picture of when hormone therapy might still be the right call, our piece on [when to start HRT](/blog/when-to-start-hrt-timing-and-the-window-of-opportunity) walks through the window of opportunity.

The most common side effects of Lynkuet are headache, fatigue, drowsiness, and mild liver enzyme elevations. In the OASIS trials, headache affected about 11% of users (vs 8% on placebo), and somnolence affected about 7%. Most side effects were mild and resolved within the first 2–4 weeks. Liver enzyme elevations were reported in roughly 2.6% of users — lower than the rate seen with fezolinetant in initial trials — and the FDA still requires baseline liver function tests plus a follow-up at 3 months, though not the ongoing monthly schedule that Veozah originally required. Serious adverse events were rare. Importantly, Lynkuet does not cause breast tenderness, breakthrough bleeding, or breast density changes, all of which are common reasons women discontinue HRT. It also does not appear to affect blood pressure or weight.

Lynkuet's cash price runs roughly $550 per month in early 2026, similar to other branded menopause medications. Insurance coverage is expanding quickly. Major commercial insurers added the drug to formularies in Q1 2026, typically at tier 3 with prior authorization, while Medicare Part D plans are still in the process of finalizing coverage. Bayer offers a manufacturer savings card that brings the cost to as low as $25 per month for commercially insured patients during the first year. For uninsured or underinsured women, patient assistance is available through Bayer's MyLynkuet Connect program. Costs vary considerably by region and pharmacy — using GoodRx or Cost Plus Drugs can save 15–30%. Always ask about the manufacturer savings card before paying cash. If your insurance denies coverage, the appeal pathway typically requires documentation that HRT was tried and failed, or that HRT is contraindicated.

Ask your doctor about Lynkuet if you have moderate-to-severe hot flashes that are interrupting your sleep, work, or quality of life — and you are not a great candidate for HRT (or you have tried it without enough benefit). Bring three things to the appointment: a one-week symptom log (count of hot flashes per day, how many wake you at night, severity from 1–10), your full medical history including any breast cancer or clot history, and a list of medications and supplements you are taking. Many prescribers are now comfortable starting Lynkuet first-line, similar to how Veozah has been positioned. If your provider is unfamiliar with the drug, gynecologists, menopause specialists, and telehealth menopause clinics typically have the most current familiarity. For night sweats specifically, our guide on [night sweats causes and treatments](/blog/night-sweats-in-menopause-causes-and-treatments-that-stop-them) covers the full ladder of options.